Preparation and characterization of polymeric nanoparticles loaded with the flavonoid luteolin, by using factorial design

International Journal of Drug Delivery

Volumn 3, Issue 4, 2011, Pages 683-698

  Puhl, Ana Cristina ^a   Fagundes, Michelle ^a   dos Santos, Karen Cristina ^b   Polikarpov, Igor ^a   das Graças Fernandes da Silva, Maria Fátima ^b   Fernandes, João Batista ^b   Vieira, Paulo Cezar ^b   Forim, Moacir Rossi ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

Author keywords

Characterization; Factorial design; Luteolin; Polymeric nanoparticles; Release kinetics

Indexed keywords

FLAVONOID; LUTEOLIN; NANOCAPSULE; NANOPARTICLE; NANOSPHERE; OLEIC ACID; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; ACETONE; DRUG SOLVENT; ISODECYLOLEIC ACID; POLYSORBATE 80; SORBITAN STEARATE; UNCLASSIFIED DRUG;

ARTICLE; COLLOID; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; EVALUATION RESEARCH; FACTORIAL DESIGN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NANOANALYSIS; NANOCHEMISTRY; NANOENCAPSULATION; NANOPHARMACEUTICS; PARTICLE SIZE; PH MEASUREMENT; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; PRODUCT RECOVERY; SURFACE PROPERTY; TIMED DRUG RELEASE; ZETA POTENTIAL; DISPERSION; DRUG RELEASE; DRUG SYNTHESIS; FACTORIAL ANALYSIS; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MATHEMATICAL ANALYSIS; MORPHOLOGY; PH; QUANTITATIVE ANALYSIS; SUSPENSION;

EID: 84863908658     PISSN: None     EISSN: 09754415     Source Type: Journal    
DOI: 10.5138/430     Document Type: Article

References (35)

1. Frishman WH, Beravol P, Carosella C. Alternative and complementary medicine for preventing and treating cardiovascular disease. Dis Mon. 2009; 55:121-192.
2. Capasso R, Izzo AA, Pinto L, Bifulco T, Vitobello C, Mascolo N. Phytotherapy and quality of herbal medicines. Fitoterapia. 2000; 71: S58-S65.
3. Zhang J, Wider B, Shang H, Li X, Ernst E. Quality of herbal medicines: challenges and solutions. Complement Ther Med. 2011; doi:10.1016/j.ctim.2011.09.004.
4. Del Rio JA, Fuster MD, Gomez P, Porras I, Garcia-Lidon A, Ortuno A. Citrus limon: a source of flavonoids of pharmaceutical interest. Food Chemistry 2004; 84: 457-461.
5. Havsteen B. The biochemistry and medical significance of the flavonoids. Pharmacol Ther. 2002; 96: 67-202.
6. Lopez-Lazaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem. 2009; 9:31-59.
7. Choi C, Jung H, Kang S, Choi J. Antioxidant constituents and a new triterpenoid glycoside from Flos Lonicerae. Arch Pharm Res 2007; 30:1-7.
8. Miyazawa M, Hisama M. Antimutagenic activity of flavonoids from Chrysanthemum morifolium. Biosci Biotechnol Biochem 2003; 67:2091-2099.
9. Lin Y, Shi RX, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets. 2008; 8: 634-646
10. Bell LN. Stability testing of nutraceuticals and functional foods. In: Wildman REC, editor. Handbook of nutraceuticals and functional foods. New York, USA: CRC Press.; 2001. p. 501-516.
11. Fessi H, Puisieux F, Devissaguet J-P, Ammoury N, Benita S. Nanocapsule formulation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989; 55: R1-R4.
12. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotech Biol Med. 2006; 2: 53-65.
13. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloid Surfaces B. 2010; 75: 1-18.
14. Ajazuddin, Saraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010; 81: 680-689.
15. Kanno S, Tomizawa A, Ohtake T, Koiwai K, Ujibe M, Ishikawa M. Naringenin-induced apoptosis via activation of NF-kappaB and necrosis involving the loss of ATP in human promyeloleukemia HL-60 cells. Toxicol Lett. 2006; 166:131-139.
16. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN. Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J Control Release. 2006; 113:189-207.
17. Krishnakumar N, Sulfikkarali N, Prasad NR, Karthikeyan S. Enhanced anticancer activity of naringenin-loaded nanoparticles in human cervical (HeLa) cancer cells. In: Biomedicine and preventive nutrition, V.1(4). Elsevier Masson SAS; 2011. p. 223-231.
18. Das S, Mandal AK, Ghosh A, Panda S, Das N, Sarkar S. Nanoparticulated quercetin in combating age related cerebral oxidative injury. Curr Aging Sci. 2008; 1:169-174.
19. Gao Y, Gu W, Chen L, Xu Z, Li Y. The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials. 2008; 29: 4129-4136.
20. Dube A, Nicolazzo JA, Larson I. Chitosan nanoparticles enhance the plasma exposure of (-)-epigallocatechin gallate in mice through an enhancement in intestinal stability. Eur J Pharm Sci. 2011; 44:422-426.
21. ICH [International Conference on Harmonization, FDA, USA]. Q2B: Validation of analytical procedures: methodology. 1996 (Available under: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073384.pdf).
22. Levy MY, Benita S. Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int J Pharm. 1990; 66: 29-37.
23. Schaffazick SR, Pohlmann AR, Mezzalira G, Guterres SS. Development of nanocapsule suspensions and nanocapsule spray-dried powders containing melatonin. J Braz Chem Soc. 2006; 17: 562-569.
24. Kim H, Kim H-W, Jung S. Aqueous solubility enhancement of some flavones by complexation with cyclodextrins. Bull Korean Chem Soc. 2008; 29: 590-594.
25. Santos KC, Da Silva, MFGF, Fernandes JB, Vieira PC, Polikarpov I, Zucolotto V, Forim MR. Development and validation of a fast RP-HPLC method to determine the analogue of the thyroid hormone, 3,5,30-triiodothyroacetic acid (TRIAC), in polymeric nanoparticles. Anal Methods. 2011; 3: 1936-1942.
26. Govender T, Stolnik S, Garnett, MC, Illum L, Davis SS. PLGA nanoprticles prepared by nanopreciptation: drug loading and release studies of a water soluble drug. J Control Release. 1999; 57: 171-185.
27. Wei XW, Gong CY, Gou M, Fu SZ, Guo Q, Shi S, Luo F, Guo G, Qiu LY, Qian ZY. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm. 2009; 1: 1-18.
28. Lacerda SP, Cerize NNP, Ré MI. Preparation and characterization of carnauba wax nanostructured lipid carriers containing benzophenone-3. Int J Cosmetic Science. 2011; 33: 312-321.
29. Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optmisation. Int J Pharm. 2004; 280: 241-251.
30. Hackley VA, Clogston JD. Measuring the hydrodynamic size of nanoparticles in aqueous media using batch-mode dynamic light scattering. In.: McNeil SE, editor. Characterization of nanoparticles intended for drug delivery. New York: Humana Press. 2011. p.35-52.
31. De Melo NFS, Grillo R, Rosa AH, Fraceto LF, Dias-Filho NL, De Paula E, Araújo, DR. Desenvolvimento e caracterização de nanocápsulas de poli(L-lactídeo) contendo benzocaína. Quim Nova. 2010; 33: 65-69.
32. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011; 63: 456-469.
33. Clogston JD, Patri AK. Zeta Potential Measurement. In.: McNeil SE, editor. Characterization of nanoparticles intended for drug delivery. New York: Humana Press. 2011. p.63-70.
34. Teixeira M, Alonso MJ, Pinto MMM, Barbosa CM. Development and characterization of PLGA nanospheres and nanocapsules containg xanthone and 3-methoxyxanthone. Eur J Pharm. Biopharm. 2005; 59: 491-500.
35. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Int. J. Pharm. 1983; 15, 25.